p300 degrader / Aurigene, Dr. Reddy’s - LARVOL DELTA

Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers (AACR 2026) - "In summary, we have identified highly selective degraders of p300 with desirable profile. Efforts are in progress towards nominating a development candidate by Q1 2026."

IO biomarker • Bladder Cancer • Breast Cancer • Diffuse Large B Cell Lymphoma • Estrogen Receptor Positive Breast Cancer • Genito-urinary Cancer • Hematological Malignancies • Hormone Receptor Breast Cancer • Melanoma • Neuroblastoma • Oncology • Prostate Cancer • Solid Tumor • AR • BRCA • BRCA1 • BRD4 • CRBN • EP300 • ER • FOXP3 • GSPT1 • HIF1A • MYC • MYCN • PD-L1

Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and p300-dependent malignancies (AACR 2024) - "In summary, we have identified highly selective degraders of p300 with desirable profile. Efforts are underway to advance them further towards nominating a development candidate."

IO biomarker • Preclinical • Synthetic lethality • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Genito-urinary Cancer • Hematological Malignancies • Hormone Receptor Breast Cancer • Lung Cancer • Neuroblastoma • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • AR • BRCA • BRCA1 • BRD4 • EP300 • ER • FOXP3 • HIF1A • MYC • MYCN • PD-L1